drugset / Trial / NCT02987114

A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

NCT02987114 ↗

Phase 2 Completed 16 enrolled PhytoTech Therapeutics, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy. Study will include a 4-week observation period ,12 weeks of treatment and 2 weeks of follow up.

Timeline

Start
2017-02-13
Primary completion
2018-06-28
Completion
2018-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject PTL 101 Unknown 25 mg/kg Oral
Subject PTL 101 Unknown 450 mg Oral

Indications